Basilea Announces Health Canada Approves ZEVTERA to Treat Bacterial Lung Infections

Basilea Pharmaceutica Ltd. BPMUF announced today that Health Canada has approved ZEVTERA (ceftobiprole medocaril) for the treatment of patients 18 years of age and older with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP). ZEVTERA® is a broad-spectrum antibiotic with bactericidal activity against susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), and Gram-negative bacteria associated with pneumonia.1 ZEVTERA® is not yet launched in Canada. Prof. Achim Kaufhold, Basilea's Chief Medical Officer, said: "We are very pleased that ZEVTERA has received regulatory approval in Canada. As a bactericidal cephalosporin with broad-spectrum activity against relevant pathogens causing pneumonia, ZEVTERA may potentially offer a valuable new treatment option in the empiric treatment setting for life-threatening lung infections." David Veitch, Basilea's Chief Commercial Officer, stated: "The approval by Health Canada is a significant achievement for Basilea and demonstrates our commitment to expand the availability of ZEVTERA around the world." About hospital-acquired and See full press release